Substance P and affective disorders: New treatment opportunities by neurokinin 1 receptor antagonists?

Neuropsychobiology

Volumn 45, Issue SUPPL. 1, 2002, Pages 2-6

  Lieb, Klaus ^a   Treffurth, Yvonne ^a   Berger, Mathias ^a   Fiebich, Bernd L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bipolar affective disorders; Depressive disorder; Mental disorders; MK 869; Neurokinin; Neurokinin 1 receptor; Neurokinin 1 receptor antagonists; Schizophrenia; Substance P

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; APREPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; PAROXETINE; SUBSTANCE P; VALPROIC ACID;

AFFECTIVE NEUROSIS; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; NEUROPSYCHIATRY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; BIPOLAR DISORDER; HUMANS; MOOD DISORDERS; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 0036122109     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049254     Document Type: Review

References (40)

1. Neurotransmitter functions of mammalian tachykinins
2. The tachykinin NK1 receptor. II. Distribution and pathophysiological roles
3. Distribution of substance P and enkephalin immunoreactive neurons and fibers
4. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain
5. Modulation of acetylcholine release in human cortical slices: Possible implications for Alzheimer's disease
6. Stress-induced C-fos expression in the rat locus coeruleus is dependent on neurokinin 1 receptor activation
7. Substance P and neurodegenerative disorders: A speculative review
8. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists
9. Substance P
10. Neurokinin antagonists
11. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist
12. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists
13. Substance P afferents have synaptic contacts with dopaminergic neurons in the ventral tegmental area of the rat
14. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test
15. NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats
16. The NK1-receptor antagonist NKP608 has an antide-pressant-like effect in the chronic mild stress model of depression in rats
17. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P
18. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
19. Reduction of substance P after chronic antidepressant treatment in the striatum, substantia nigra and amygdala of the rat
20. Elevation of substance P-like peptides in the CSF of psychiatric patients
21. CSF substance P immunoreactivity in affective disorders
22. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders
23. Polymorphism of the gene of angiotensin converting enzyme: Lack of association with mood disorder
24. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia
25. Can the placebo be the cure?
26. Substance P antagonists: Novel agents in the treatment of depression
27. Effects of lithium and haloperidol administration on the rat brain levels of substance P
28. Lithium increases rat striatal beta- and gamma-preprotachykinin messenger RNAs
29. Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain
30. Effects of lithium on neuropeptide Y, neurokinin A and substance P in brain and peripheral tissues of the rat
31. Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: Lithium treatment normalizes tachykinins
32. Intravenous valproate loading in acutely manic and depressed bipolar I patients
33. Functional substance P receptors on a human astrocytoma cell line (U-373 MG)
34. Effects of substance P and selected other neuropeptides on the synthesis of interleukin-1 beta and interleukin-6 in human monocytes: A re-examination
35. Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and nuclear factor IL-6
36. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission
37. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappaB
38. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness
39. Stimulation of ACTH/cortisol by intravenously infused substance P in normal men: Inhibition by sodium valproate
40. Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts